{"id":"elidel-pimecrolimus-1","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Application site burning or irritation"},{"rate":"5–10","effect":"Pruritus"},{"rate":"5–8","effect":"Skin infection (secondary bacterial or viral)"},{"rate":"2–5","effect":"Folliculitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pimecrolimus binds to calcineurin and inhibits its phosphatase activity, preventing the dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the transcription of pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ, thereby reducing local immune activation and inflammation in atopic dermatitis and other inflammatory skin conditions.","oneSentence":"Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:50.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (eczema)"},{"name":"Allergic contact dermatitis"},{"name":"Seborrheic dermatitis"}]},"trialDetails":[{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390},{"nctId":"NCT00568997","phase":"","title":"10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-06-27","conditions":"Atopic Dermatitis","enrollment":8000},{"nctId":"NCT02376049","phase":"PHASE1","title":"A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT06052995","phase":"","title":"Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.","status":"UNKNOWN","sponsor":"MEDA PHARMA SPA, a Viatris company","startDate":"2023-11","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":130},{"nctId":"NCT04976868","phase":"","title":"Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2021-03-18","conditions":"Atopic Dermatitis","enrollment":130},{"nctId":"NCT05729074","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-13","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":80},{"nctId":"NCT01082393","phase":"PHASE4","title":"Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-02-16","conditions":"Vitiligo","enrollment":14},{"nctId":"NCT00403559","phase":"PHASE2","title":"A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Dermatology Specialists Research","startDate":"2007-05-07","conditions":"Seborrheic Dermatitis","enrollment":113},{"nctId":"NCT03107611","phase":"PHASE3","title":"Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2016-02-29","conditions":"Atopic Dermatitis","enrollment":654},{"nctId":"NCT00120523","phase":"PHASE3","title":"5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2004-04","conditions":"Atopic Dermatitis","enrollment":2418},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT04900948","phase":"PHASE4","title":"Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life","status":"COMPLETED","sponsor":"National Medical Research Center for Children's Health, Russian Federation","startDate":"2017-12-10","conditions":"Atopic Dermatitis","enrollment":108},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT02791308","phase":"PHASE3","title":"Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02","conditions":"Atopic Dermatitis","enrollment":587},{"nctId":"NCT00128245","phase":"PHASE2","title":"Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Keratoconjunctivitis Sicca","enrollment":440},{"nctId":"NCT00208026","phase":"PHASE1, PHASE2","title":"Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2005-09","conditions":"Netherton Syndrome","enrollment":3},{"nctId":"NCT02896101","phase":"PHASE3","title":"Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2016-08","conditions":"Atopic Dermatitis","enrollment":755},{"nctId":"NCT03834935","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba","status":"UNKNOWN","sponsor":"St Joseph University, Beirut, Lebanon","startDate":"2019-03-01","conditions":"Pityriasis Alba","enrollment":40},{"nctId":"NCT00222183","phase":"NA","title":"Cutaneous Lupus Erythematosus and Elidel","status":"WITHDRAWN","sponsor":"University of Leipzig","startDate":"2003-06","conditions":"Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid","enrollment":""},{"nctId":"NCT00509990","phase":"PHASE4","title":"Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-04","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT03297502","phase":"PHASE3","title":"Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2016-06","conditions":"Atopic Dermatitis","enrollment":582},{"nctId":"NCT01692626","phase":"PHASE2","title":"1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-02","conditions":"Rash","enrollment":13},{"nctId":"NCT00367393","phase":"PHASE4","title":"Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-03","conditions":"Atopic Dermatitis","enrollment":41},{"nctId":"NCT00925730","phase":"PHASE4","title":"Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-03","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00510003","phase":"PHASE4","title":"Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-12","conditions":"Atopic Dermatitis","enrollment":117},{"nctId":"NCT02583022","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis","status":"COMPLETED","sponsor":"Amorepacific Corporation","startDate":"2013-06","conditions":"Atopic Dermatitis","enrollment":74},{"nctId":"NCT02443311","phase":"PHASE4","title":"Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2010-09","conditions":"Oral Lichen Planus","enrollment":24},{"nctId":"NCT00568412","phase":"PHASE4","title":"A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Mild to Moderate Atopic Dermatitis","enrollment":80},{"nctId":"NCT00666159","phase":"PHASE4","title":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Dermatitis, Atopic","enrollment":226},{"nctId":"NCT00666302","phase":"PHASE4","title":"A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-10","conditions":"Dermatitis, Atopic","enrollment":413},{"nctId":"NCT00667160","phase":"PHASE4","title":"Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Dermatitis, Atopic","enrollment":426},{"nctId":"NCT00610142","phase":"PHASE2","title":"Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2007-12","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00655512","phase":"PHASE1","title":"Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2008-01","conditions":"Healthy","enrollment":40},{"nctId":"NCT00393263","phase":"PHASE2","title":"Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus","status":"COMPLETED","sponsor":"Center for Vulvovaginal Disorders","startDate":"2006-10","conditions":"Lichen Sclerosus","enrollment":38},{"nctId":"NCT00946478","phase":"NA","title":"Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2009-10","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT00322569","phase":"PHASE3","title":"A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)","status":"COMPLETED","sponsor":"Cordis US Corp.","startDate":"2006-07","conditions":"Coronary Disease","enrollment":246},{"nctId":"NCT00297037","phase":"PHASE2","title":"Pimecrolimus Cream for Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-08","conditions":"Oral Lichen Planus","enrollment":21},{"nctId":"NCT01524744","phase":"PHASE2","title":"A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2009-03","conditions":"Oral Lichen Planus","enrollment":40},{"nctId":"NCT01202149","phase":"PHASE4","title":"Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Frankel, Amylynne, M.D.","startDate":"2010-03","conditions":"Eczema, Atopic Dermatitis","enrollment":30},{"nctId":"NCT00124709","phase":"PHASE4","title":"Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-10","conditions":"Atopic Dermatitis","enrollment":1091},{"nctId":"NCT01177566","phase":"PHASE4","title":"Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.","status":"COMPLETED","sponsor":"Emer, Jason, M.D.","startDate":"2009-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00119158","phase":"PHASE4","title":"Combination Therapy for Atopic Dermatitis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-10","conditions":"Atopic Dermatitis","enrollment":90},{"nctId":"NCT00507832","phase":"PHASE2","title":"Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2007-04","conditions":"Prurigo Nodularis","enrollment":30},{"nctId":"NCT01132079","phase":"NA","title":"Pimecrolimus and Epidermal Barrier Function","status":"COMPLETED","sponsor":"University of Kiel","startDate":"2005-03","conditions":"Atopic Dermatitis","enrollment":15},{"nctId":"NCT00810862","phase":"PHASE4","title":"Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children","status":"TERMINATED","sponsor":"Children's Hospital of Michigan","startDate":"2006-11","conditions":"Atopic Dermatitis","enrollment":18},{"nctId":"NCT00139581","phase":"PHASE4","title":"Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT00226707","phase":"PHASE3","title":"Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-07","conditions":"Chronic Hand Dermatitis","enrollment":652},{"nctId":"NCT00608673","phase":"NA","title":"Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-04","conditions":"Discoid Lupus Erythematosus","enrollment":10},{"nctId":"NCT00150059","phase":"PHASE4","title":"Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-12","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT00484003","phase":"PHASE4","title":"A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Atopic Eczema","enrollment":""},{"nctId":"NCT00460083","phase":"PHASE4","title":"Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Ceragenix Pharmaceuticals","startDate":"2007-04","conditions":"Atopic Dermatitis","enrollment":35},{"nctId":"NCT00232115","phase":"PHASE3","title":"Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-09","conditions":"Perioral Dermatitis","enrollment":124},{"nctId":"NCT00351052","phase":"PHASE3","title":"Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2001-12","conditions":"Atopic Dermatitis","enrollment":184},{"nctId":"NCT00120302","phase":"PHASE4","title":"Quality of Life Study in Adults With Facial Eczema","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-03","conditions":"Atopic Dermatitis","enrollment":76},{"nctId":"NCT00130364","phase":"PHASE4","title":"Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-08","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT00121381","phase":"PHASE4","title":"Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Dermatitis, Atopic","enrollment":400},{"nctId":"NCT00121316","phase":"PHASE4","title":"Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT00117377","phase":"PHASE4","title":"Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-04","conditions":"Atopic Dermatitis","enrollment":70},{"nctId":"NCT00231998","phase":"PHASE3","title":"Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-05","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT00232011","phase":"PHASE3","title":"Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-05","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT00321750","phase":"PHASE2","title":"Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2004-12","conditions":"Oral Erosive Lichen Planus","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":147,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Elidel (pimecrolimus 1%)","genericName":"Elidel (pimecrolimus 1%)","companyName":"St Joseph University, Beirut, Lebanon","companyId":"st-joseph-university-beirut-lebanon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin. Used for Atopic dermatitis (eczema), Allergic contact dermatitis, Seborrheic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}